FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4214889712> ?p ?o ?g. }

• W4214889712 endingPage "262" @default.
• W4214889712 startingPage "253" @default.
• W4214889712 abstract "We describe the results of an exploratory analysis performed on the first head-to-head study (JapicCTI-194611) comparing two different intravenous (IV) neurokinin 1 (NK1) receptor antagonists, fosnetupitant and fosaprepitant, in combination with palonosetron (PALO) and dexamethasone (DEX) for the prevention of highly emetogenic chemotherapy (HEC)-induced nausea and vomiting (CINV). This analysis was performed to validate the findings of the primary analysis (previously published) utilizing a last observation carried forward (LOCF) approach for missing values for the efficacy endpoint of complete response (no emetic event and no rescue medication), while also evaluating the time periods encompassing the 0–168-hour (h) “extended overall phase” interval. Patients scheduled to receive cisplatin-based chemotherapy were randomized 1:1 to fosnetupitant 235 mg or fosaprepitant 150 mg in combination with PALO 0.75 mg and DEX. Complete response rates were calculated and compared (stratified by age category and sex with a Mantel–Haenszel test) during the study’s primary overall phase (0–120 h) and during additional time intervals of interest [acute (0–24 h), delayed (24–120 h), extended delayed (> 24–168 h), beyond delayed (120–168 h), and extended overall (0–168 h)]. A total of 785 patients were included (fosnetupitant N = 392, fosaprepitant N = 393). Complete response rates were numerically higher for fosnetupitant versus fosaprepitant for all time intervals and statistically significant for the extended overall phase. Complete response rates for fosnetupitant versus fosaprepitant during the overall, acute, delayed, extended delayed, beyond delayed, and extended overall phases were 75.5% vs. 71.0% (p = 0.1530), 93.9% vs. 92.6% (p = 0.4832), 77.0% vs. 72.8% (p = 0.1682), 74.7% vs. 68.4% (p = 0.0506), 86.7% vs. 81.7% (p = 0.0523), and 73.5% vs. 66.9% (p = 0.0450), respectively. In this exploratory analysis, fosnetupitant appeared to be more effective than fosaprepitant in preventing CINV associated with cisplatin-based HEC during the extended 7-day period following chemotherapy." @default.
• W4214889712 created "2022-03-05" @default.
• W4214889712 creator A5002745221 @default.
• W4214889712 creator A5005542616 @default.
• W4214889712 creator A5013107055 @default.
• W4214889712 creator A5034162457 @default.
• W4214889712 creator A5034349158 @default.
• W4214889712 creator A5035668565 @default.
• W4214889712 creator A5050855780 @default.
• W4214889712 creator A5058561701 @default.
• W4214889712 creator A5066075096 @default.
• W4214889712 creator A5070125088 @default.
• W4214889712 creator A5080846994 @default.
• W4214889712 creator A5080938148 @default.
• W4214889712 creator A5084498556 @default.
• W4214889712 date "2022-03-04" @default.
• W4214889712 modified "2023-10-01" @default.
• W4214889712 title "Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE)" @default.
• W4214889712 cites W1968008450 @default.
• W4214889712 cites W1974362328 @default.
• W4214889712 cites W1993434718 @default.
• W4214889712 cites W2037750236 @default.
• W4214889712 cites W2038182557 @default.
• W4214889712 cites W2074100969 @default.
• W4214889712 cites W2083670498 @default.
• W4214889712 cites W2123667342 @default.
• W4214889712 cites W2302072111 @default.
• W4214889712 cites W2324201257 @default.
• W4214889712 cites W2527377692 @default.
• W4214889712 cites W2730503915 @default.
• W4214889712 cites W2964946892 @default.
• W4214889712 cites W3153717930 @default.
• W4214889712 cites W4226542090 @default.
• W4214889712 doi "https://doi.org/10.1007/s40487-022-00188-2" @default.
• W4214889712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35246827" @default.
• W4214889712 hasPublicationYear "2022" @default.
• W4214889712 type Work @default.
• W4214889712 citedByCount "7" @default.
• W4214889712 countsByYear W42148897122023 @default.
• W4214889712 crossrefType "journal-article" @default.
• W4214889712 hasAuthorship W4214889712A5002745221 @default.
• W4214889712 hasAuthorship W4214889712A5005542616 @default.
• W4214889712 hasAuthorship W4214889712A5013107055 @default.
• W4214889712 hasAuthorship W4214889712A5034162457 @default.
• W4214889712 hasAuthorship W4214889712A5034349158 @default.
• W4214889712 hasAuthorship W4214889712A5035668565 @default.
• W4214889712 hasAuthorship W4214889712A5050855780 @default.
• W4214889712 hasAuthorship W4214889712A5058561701 @default.
• W4214889712 hasAuthorship W4214889712A5066075096 @default.
• W4214889712 hasAuthorship W4214889712A5070125088 @default.
• W4214889712 hasAuthorship W4214889712A5080846994 @default.
• W4214889712 hasAuthorship W4214889712A5080938148 @default.
• W4214889712 hasAuthorship W4214889712A5084498556 @default.
• W4214889712 hasBestOaLocation W42148897121 @default.
• W4214889712 hasConcept C126322002 @default.
• W4214889712 hasConcept C168563851 @default.
• W4214889712 hasConcept C203092338 @default.
• W4214889712 hasConcept C2776712918 @default.
• W4214889712 hasConcept C2779924295 @default.
• W4214889712 hasConcept C2780401358 @default.
• W4214889712 hasConcept C2780574406 @default.
• W4214889712 hasConcept C2780580376 @default.
• W4214889712 hasConcept C2780852908 @default.
• W4214889712 hasConcept C2780884295 @default.
• W4214889712 hasConcept C42219234 @default.
• W4214889712 hasConcept C71924100 @default.
• W4214889712 hasConcept C90924648 @default.
• W4214889712 hasConceptScore W4214889712C126322002 @default.
• W4214889712 hasConceptScore W4214889712C168563851 @default.
• W4214889712 hasConceptScore W4214889712C203092338 @default.
• W4214889712 hasConceptScore W4214889712C2776712918 @default.
• W4214889712 hasConceptScore W4214889712C2779924295 @default.
• W4214889712 hasConceptScore W4214889712C2780401358 @default.
• W4214889712 hasConceptScore W4214889712C2780574406 @default.
• W4214889712 hasConceptScore W4214889712C2780580376 @default.
• W4214889712 hasConceptScore W4214889712C2780852908 @default.
• W4214889712 hasConceptScore W4214889712C2780884295 @default.
• W4214889712 hasConceptScore W4214889712C42219234 @default.
• W4214889712 hasConceptScore W4214889712C71924100 @default.
• W4214889712 hasConceptScore W4214889712C90924648 @default.
• W4214889712 hasFunder F4320311653 @default.
• W4214889712 hasIssue "1" @default.
• W4214889712 hasLocation W42148897121 @default.
• W4214889712 hasLocation W42148897122 @default.
• W4214889712 hasLocation W42148897123 @default.
• W4214889712 hasLocation W42148897124 @default.
• W4214889712 hasOpenAccess W4214889712 @default.
• W4214889712 hasPrimaryLocation W42148897121 @default.
• W4214889712 hasRelatedWork W100286279 @default.
• W4214889712 hasRelatedWork W1480067006 @default.
• W4214889712 hasRelatedWork W1502901901 @default.
• W4214889712 hasRelatedWork W2032692004 @default.
• W4214889712 hasRelatedWork W2057039455 @default.
• W4214889712 hasRelatedWork W2060030856 @default.
• W4214889712 hasRelatedWork W2398280039 @default.
• W4214889712 hasRelatedWork W2416018394 @default.
• W4214889712 hasRelatedWork W2953429140 @default.
• W4214889712 hasRelatedWork W4382581927 @default.

• next